[{"id":"8cf717b4-4e12-47ef-a4a5-e6aa2eeff806","acronym":"","url":"https://clinicaltrials.gov/study/NCT02029157","created_at":"2021-01-18T09:17:58.068Z","updated_at":"2024-07-02T16:37:17.245Z","phase":"Phase 3","brief_title":"A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT02029157","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" MET-H","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • tivantinib (ARQ 197)"],"overall_status":"Completed","enrollment":" Enrollment 386","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 08/01/2017","primary_completion_date":" 08/01/2017","study_txt":" Completion: 08/01/2017","study_completion_date":" 08/01/2017","last_update_posted":"2017-10-09"}]